{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:07:35Z","timestamp":1792760855468,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"abstract":"<jats:p>\n                    This retrospective cohort study evaluated the tolerability, efficacy, and safety of adjunctive cannabidiol (CBD) therapy in pediatric-onset intractable epilepsy across diverse genetic and nongenetic etiologies. Twenty-nine patients aged 6 to 24 years, treated at Korea University Hospitals between April 2019 and May 2024, were included. The median follow-up duration was 14.3 months. Confirmed genetic etiologies included\n                    <jats:italic toggle=\"yes\">SCN1A<\/jats:italic>\n                    -related epilepsy (6.9%);\n                    <jats:italic toggle=\"yes\">GABRB3<\/jats:italic>\n                    -,\n                    <jats:italic toggle=\"yes\">SCN2A<\/jats:italic>\n                    -,\n                    <jats:italic toggle=\"yes\">KCNT1<\/jats:italic>\n                    -,\n                    <jats:italic toggle=\"yes\">KIF1A<\/jats:italic>\n                    -, and\n                    <jats:italic toggle=\"yes\">COL4A1<\/jats:italic>\n                    -related epilepsies (3.4% each); Angelman syndrome and Down syndrome (3.4% each). Presumed genetic etiologies included hemimegalencephaly (3.4%) and cortical dysplasia (6.9%). Acquired causes included hypoxic brain injury (6.9%) and CNS infection (10.3%). In 41.4% of cases, the etiology was unidentified; among them, 58.3% had a history of infantile spasms. At CBD initiation, patients were receiving a median of 5 antiseizure medications, most commonly valproic acid (93.1%), clobazam (82.8%), and levetiracetam (75.9%). The median maintenance dose of CBD was 14.2\u2009mg\/kg\/d. The retention rate was above 86% at both 12 and 24 months. At 12 months, 79.3% achieved a \u226550% reduction in seizure frequency, and 34.5% achieved a \u226575% reduction without generalized motor seizures. One patient with a\n                    <jats:italic toggle=\"yes\">GABRB3<\/jats:italic>\n                    variant achieved seizure freedom. Adverse events occurred in 37.9%, most commonly somnolence and lethargy. These were mild and resolved with antiseizure medication adjustments. CBD was discontinued in 3 patients due to pneumonia, lethargy, or seizure aggravation. CBD therapy demonstrated favorable retention, efficacy, and safety profiles in pediatric-onset intractable epilepsy across a spectrum of etiologies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047425","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T17:00:33Z","timestamp":1769965233000},"page":"e47425","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Adjunctive cannabidiol in intractable pediatric epilepsy: A retrospective study on tolerability, efficacy, and safety across genetic and nongenetic etiologies"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-4702","authenticated-orcid":false,"given":"Youngkyu","family":"Shim","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan-si, Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hwa","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hye","family":"Byeon","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8735-292X","authenticated-orcid":false,"given":"Baik-Lin","family":"Eun","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260519","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2468-2667(20)30190-0","article-title":"The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017.","volume":"5","author":"Deuschl","year":"2020","journal-title":"Lancet Public Health"},{"key":"R2-20260519","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on therapeutic strategies.","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R3-20260519","doi-asserted-by":"crossref","first-page":"23462","DOI":"10.1038\/s41598-021-02770-6","article-title":"Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis.","volume":"11","author":"Treves","year":"2021","journal-title":"Sci Rep"},{"key":"R4-20260519","doi-asserted-by":"crossref","first-page":"104822","DOI":"10.1016\/j.phrs.2020.104822","article-title":"Cannabis sativa: much more beyond \u03949-tetrahydrocannabinol.","volume":"157","author":"Alves","year":"2020","journal-title":"Pharmacol Res"},{"key":"R5-20260519","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.neuroscience.2021.12.013","article-title":"Targeting endocannabinoid system in epilepsy: for good or for bad.","volume":"482","author":"Mart\u00ednez-Aguirre","year":"2022","journal-title":"Neuroscience"},{"key":"R6-20260519","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy.","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord"},{"key":"R7-20260519","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2023.09.015","article-title":"Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex.","volume":"112","author":"Espinosa-Jovel","year":"2023","journal-title":"Seizure"},{"key":"R8-20260519","first-page":"47","article-title":"Cannabinoids in epilepsy: clinical efficacy and pharmacological considerations.","volume":"38","author":"Espinosa-Jovel","year":"2023","journal-title":"Neurologia (Engl Ed)"},{"key":"R9-20260519","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex.","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"R10-20260519","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/epi.17496","article-title":"Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: four-year results from the expanded access program.","volume":"64","author":"Szaflarski","year":"2023","journal-title":"Epilepsia"},{"key":"R11-20260519","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/epi4.12699","article-title":"Real-world data on cannabidiol treatment of various epilepsy subtypes: a retrospective, multicenter study.","volume":"8","author":"Kuhne","year":"2023","journal-title":"Epilepsia Open"},{"key":"R12-20260519","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","article-title":"Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US.","volume":"33","author":"Sands","year":"2019","journal-title":"CNS Drugs"},{"key":"R13-20260519","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/epi4.12411","article-title":"Add\u2010on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy.","volume":"5","author":"Kuchenbuch","year":"2020","journal-title":"Epilepsia Open"},{"key":"R14-20260519","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.yebeh.2018.05.013","article-title":"Open-label use of highly purified CBD (Epidiolex\u00ae) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes.","volume":"86","author":"Devinsky","year":"2018","journal-title":"Epilepsy Behav"},{"key":"R15-20260519","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"R16-20260519","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs.","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"R17-20260519","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions.","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"R18-20260519","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ane.13351","article-title":"Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.","volume":"143","author":"Gunning","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"R19-20260519","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.seizure.2022.01.001","article-title":"Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy.","volume":"95","author":"Caraballo","year":"2022","journal-title":"Seizure"},{"key":"R20-20260519","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41467-022-29280-x","article-title":"Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies.","volume":"13","author":"Absalom","year":"2022","journal-title":"Nat Commun"},{"key":"R21-20260519","doi-asserted-by":"crossref","first-page":"fcaa162","DOI":"10.1093\/braincomms\/fcaa162","article-title":"Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies.","volume":"2","author":"Absalom","year":"2020","journal-title":"Brain Commun"},{"key":"R22-20260519","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1111\/epi.17336","article-title":"Molecular and clinical descriptions of patients with GABA(A) receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): a cohort study, review of literature, and genotype-phenotype correlation.","volume":"63","author":"Maillard","year":"2022","journal-title":"Epilepsia"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T13:03:52Z","timestamp":1779195832000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047425","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"2025-02-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}